

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:	Hardin et al.	§	ART UNIT NO.: 1645
SERIAL NO.:	10/007,621	. §	EXAMINER: UNKNOWN
FILED:	12/03/01	§	DOCKET NO.:00007/02UTL
		, 0	

•	§
TITLE: Enzymatic Nucleic Acid Synthesis:	. 8
Compositions and Methods for Altering	
Monomer Incorporation Fidelity	8

EV-123 140 882 US	CERTIFICATE OF MAIL BY EXPRESS MAIL 12 December 2002
Express Mail Mumber	Date of Deposi
	hay this paper or fee is being deposited with the United States Postal Service "Express Mail service "Express Mail service under 37 C.F.R. \$110 on the date indicated above and is addressed to the
1 MATH	Assistant Commissioner of Patent
- Robert Wastrobi	BOX SEQUENCE 12 December 200: Washington, D.C. 20231 Date of Signature

STATEMENT REGARDING SUBSTITUTE PAPER COPY OF SEQUENCE LISTING AND CRF COPY OF SEQUENCE LISTING

Dear Sir/Madam:

In response to a Notice to Comply with Sequence Rules, Applicant used the PatentIn 3.1 software for the United States Patent and Trademark Office to generate a hard copy and electronic copy of the sequence listing as required by the Notice.

Applicants' Attorney verifies that the paper and electronic listing are identical, both generated by PatentIn 3.1.

Applicants' Attorney has attempted in good faith to respond to this notice; however, Applicants' Attorney must point out that at numerous parts of the specification, reference is made to specific enzymes and DNA molecules, without the actual sequence. Applicants did not include actual sequences because the actual sequences are not germane to this application. The application relates to functionalized dNTPs or other small molecules that increase base incorporation fidelity. The invention is not related to any specific nucleic acid sequence or peptide sequence.

If this submission is considered deficient, please have someone from the sequence compliance group call me. I have attempted several times to get an answer on the issue of whether a nucleic acid or peptide sequence listing is required for a mere reference to a specific nucleic acid molecule or a specific enzyme or polypeptide, without sequence listing, in an application.

Respectfully submitted,

Date: 12 December 2002

Robert W. Strozier, Reg. No. 34,024

Attorney for Applicants